



C4X Discovery Holdings plc
("C4XD" or the "Company")

Appointment of Clive Dix as Chief Executive Officer

4th May, 2016 - C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces that Clive Dix has been appointed Chief Executive Officer with immediate effect.

Clive joined C4XD as Non-Executive Chairman in October 2014 and became Executive Chairman in November 2015. Sam Williams, Non-Executive Director, will become Interim Chairman whilst a search for a new Chairman is undertaken.

Commenting on the announcement, Clive Dix said: *"Having seen from an executive position the potential of the platform to generate entirely new compounds against high-value therapeutic targets more rapidly and efficiently than any technology I've come across before and having witnessed the interest we're receiving in C4X Discovery, I am delighted to take the helm on a full-time basis. I have never been more excited by a company than this one."*

Dr Dix is widely recognised as one of the leading figures in the UK biotechnology sector, combining track records as a serially successful entrepreneur and an experienced pharmaceutical R&D executive. Most recently, Dr Dix was CEO of Convergence Pharmaceuticals, which was sold to Biogen in January 2015 for \$675m. Prior to that, Dr Dix enjoyed successful exits with PowderMed Limited, Auralis Limited and PowderJect Pharmaceuticals plc, where he held the roles of CEO, Chairman and Head of R&D, respectively. Before his move into biotechnology, Dr Dix was UK Research Director for GlaxoWellcome. He currently serves as Chairman of Touchlight Genetics Ltd and Centauri Therapeutics Ltd, and was Chairman of the UK BiIndustry Association (BIA) from 2008-2010.

--ENDS--

For further information please contact:

C4X Discovery Holdings plc

Clive Dix, Chief Executive Officer 07801 865803

Zeus Capital Limited

Dan Bate 0161 393 1973
Dominic Wilson/Phil Walker 0203 829 5000

Consilium Strategic Communications

Mary-Jane Elliott, Chris Gardner, Matthew Neal, Chris Welsh 0203 709 5700

About C4X Discovery

C4X Discovery aims to become the world's most productive drug discovery and development company by exploiting cutting-edge technologies to design and create best-in-class drug candidates. The

Company has two proprietary and synergistic software platforms "Taxonomy3®" and "Conformetrix" that provide a significant competitive advantage when combined with an experienced management team. "Taxonomy3®" is a human genetics analysis platform that utilises a unique mathematical approach to discovery and validation of drug targets for the treatment of a variety of diseases. "Conformetrix" determines the 3D shape of drug molecules from experimental in vitro data that enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas. We have a hybrid business model of wholly-owned programmes and partnerships with pharma, biotech and academics.

The Company was founded in 2008 as a spin-out from the University of Manchester and has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically. For additional information please go to: www.c4xdiscovery.com